| MW: | 39 kDa |
| |
| Source: | Produced in insect cells. Glycosylated procathepsin F. Produced in a baculovirus expression system. |
| |
| EC: | 3.4.22.41 |
| |
| UniProt ID: | Q9UBX1 |
| |
| Formulation: | Liquid. In 20mM NaOAc, pH 5.0, 2.5mM EDTA, 250mM NaCl. |
| |
| Purity Detail: | Partially purified by single-step affinity chromatography and gel filtration. |
| |
| Activity: | Under acidic conditions (pH 4.0 optimum), procathepsin F self-cleaves to its 30 kDa active form. Procathepsin F can also be activated with pepsin. This can be monitored by SDS-PAGE, or by activity using Z-Phe-Arg-AMC (Prod. No. BML-P139) or Z-Leu-Arg-AMC (Prod. No. BML-P229) at 10µM in 100mM NaOAc, pH 5.75, 1mM EDTA, 10mM L-cysteine. |
| |
| Shipping: | Dry Ice |
| |
| Long Term Storage: | -80°C |
| |
| Scientific Background: | Cathepsin F, a member of the papain family of lysosomal cysteine proteases, acts upon proteins such as MHC Class II-associated invariant chain and ApoB-1006. It is inhibited by the cysteine proteinase inhibitor E-643 and cystatin C4. It is a lysosomal protease expressed in numerous tissues, notably brain and macrophages. It functions in the immune system and is implicated in disease states such as atherosclerosis, cancer, and angiogenesis. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
